日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors

对于新诊断的高危子宫内膜癌,帕博利珠单抗或安慰剂联合辅助化疗(伴或不伴放疗)可导致错配修复缺陷型肿瘤

Slomovitz, Brian M; Cibula, David; Lv, Weiguo; Ortaç, Fırat; Hietanen, Sakari; Backes, Floor; Kikuchi, Akira; Lorusso, Domenica; Dańska-Bidzińska, Anna; Samouëlian, Vanessa; Barretina-Ginesta, Maria-Pilar; Vulsteke, Christof; Lai, Chyong-Huey; Pothuri, Bhavana; Zhang, Yu; Magallanes-Maciel, Manuel; Amit, Amnon; Guarneri, Valentina; Zagouri, Flora; Bell, Maria; Welz, Julia; Eminowicz, Gemma; Hruda, Martin; Willmott, Lyndsay J; Lichfield, Jasmine; Wang, Wei; Orlowski, Robert; Aktan, Gursel; Gladieff, Laurence; Van Gorp, Toon

Correction: Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer

更正:高危子宫内膜癌复发疾病的临床负担

Kponee-Shovein, Kalé; Prabhu, Vimalanand S; Song, Yan; Chen, Lei; Cheng, Mu; Li, Yeran; Sun, Yezhou; Hilts, Annalise; Hua, Qi; Lichfield, Jasmine; Duska, Linda

Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer

高危子宫内膜癌复发疾病的临床负担

Kponee-Shovein, Kalé; Prabhu, Vimalanand S; Song, Yan; Chen, Lei; Cheng, Mu; Li, Yeran; Sun, Yezhou; Hilts, Annalise; Hua, Qi; Lichfield, Jasmine; Duska, Linda

Real-world clinical outcomes of patients with high-risk endometrial cancer or endometrial carcinosarcoma in England: A retrospective cohort study

英格兰高危子宫内膜癌或子宫内膜癌肉瘤患者的真实世界临床结局:一项回顾性队列研究

Prabhu, Vimalanand S; Landfeldt, Erik; Ralphs, Eleanor; Teoh, Cheryl; Ridsdale-Smith, Jess; Macey, Karen; Trankov, Nikolay; Lambova, Alexandrina; Lichfield, Jasmine; Eminowicz, Gemma

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies

内分泌单药治疗治疗内脏转移性激素受体阳性乳腺癌与非内脏转移性激素受体阳性乳腺癌的荟萃分析

Robertson, John F R; Di Leo, Angelo; Johnston, Stephen; Chia, Stephen; Bliss, Judith M; Paridaens, Robert J; Lichfield, Jasmine; Bradbury, Ian; Campbell, Christine